A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback